Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma
The combination of acalabrutinib with bendamustine-rituximab significantly improved PFS. Clinical benefit of acalabrutinib with bendamustine-rituximab was achieved with manageable toxicity.
Authors
- Jonas Paludo (ORCID: https://orcid.org/0000-0002-7350-5531)
- Yufu Li (ORCID: https://orcid.org/0000-0002-6792-9880)
- Iryna Kryachok
- Martin Dreyling (ORCID: https://orcid.org/0000-0002-0358-5249)
- Cecily J. Forsyth (ORCID: https://orcid.org/0000-0002-9108-3088)
- Robin Lesley
- Michael P. Chu (ORCID: https://orcid.org/0000-0002-2826-3342)
- David Belada (ORCID: https://orcid.org/0000-0002-4981-6188)
- Safaa Ramadan (ORCID: https://orcid.org/0000-0003-0992-3867)
- Brad S. Kahl (ORCID: https://orcid.org/0000-0003-0459-6609)
- Chan Yoon Cheah (ORCID: https://orcid.org/0000-0001-7988-1565)
- Caterina Patti (ORCID: https://orcid.org/0009-0006-4316-9254)
- Marta Morawska (ORCID: https://orcid.org/0000-0001-6836-2903)
- Juan‐Manuel Sancho (ORCID: https://orcid.org/0000-0001-7168-6538)
- Michael L. Wang (ORCID: https://orcid.org/0000-0001-9748-5486)
- Jingyang Zhang (ORCID: https://orcid.org/0000-0002-6377-1916)
- Wojciech J. Jurczak (ORCID: https://orcid.org/0000-0003-1879-8084)
- Laura Maria Fogliatto (ORCID: https://orcid.org/0000-0002-0610-7971)
- David Šálek
- Simon Rule
- Yuqin Song
Institutions
- AstraZeneca (United Kingdom) (GB)
- Medical University of Lublin (PL)
- The University of Texas MD Anderson Cancer Center (US)
- University of Alberta (CA)
- The University of Western Australia (AU)
- Peking University (CN)
- Washington University in St. Louis (US)
- Charles University (CZ)
- Gosford Hospital (AU)
- Sir Charles Gairdner Hospital (AU)
- LMU Klinikum (DE)
- Peking University Cancer Hospital (CN)
- Hospital de Clínicas de Porto Alegre (BR)
- Ospedale Vincenzo Cervello (IT)
- University Hospital Brno (CZ)
- National Institute of Oncology (HU)
- National Cancer Institute (UA)
- Mayo Clinic in Arizona (US)
- Henan Cancer Hospital (CN)
- AstraZeneca (United States) (US)
- Hospital Universitari Germans Trias i Pujol (ES)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1200/jco-25-00690
- Citations
- 36
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 58.52
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- AstraZeneca
- Sanofi
- Gilead Sciences
- Celgene
- Karyopharm Therapeutics
- TG Therapeutics
- BeiGene
- Galápagos
- Swedish Orphan Biovitrum
- MorphoSys
- Genentech
- Pharmacyclics
- Juno Therapeutics
- Cilag